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Abstract
Background Myelin oligodendrocyte glycoprotein immunoglobulin G associated optic neuritis (MOG-ON) is a recently 
described entity. Recent studies have shown that MOG-ON has a more severe clinical presentation than classic optic neuritis 
(ON).
Objective This study aimed to define morphological characteristics of MOG-ON, correlate these with clinical characteristics 
and compare them with multiple sclerosis associated ON (MS-ON) and healthy controls (CTRL).
Methods In a retrospective study, we included MOG-ON and MS-ON patients seen between 2011 and 2018 at the University 
Hospital Bern. Data from clinical examination, perimetry, and optical coherence tomography (OCT) were analyzed.
Results A total of 66 eyes of 43 patients were included; 22 MS-ON and 33 CTRL eyes were sex- and age-matched to 11 
MOG-ON eyes. We found significantly worse visual acuity at nadir, but better recovery and thinner global peripapillary 
retinal nerve fiber layer thickness in MOG-ON patients compared to MS-ON patients. Both groups exhibited irregular thin-
ning of the macular ganglion cell layer. Furthermore, the visual acuity and visual field parameters correlated to retinal layer 
thickness only in MOG-ON eyes.
Conclusion In comparison to MS-ON, MOG-ON is associated with more prominent acute vision loss and more pronounced 
global thinning of the pRNFL. Both entities result in similar final visual acuity and atrophy of the macular ganglion cell layer.
Keywords MOG · MS · Optic neuritis · RNFL · Ganglion cell layer · OCT
Introduction
The detection of myelin oligodendrocyte glycoprotein 
(MOG) antibodies in cases of optic neuritis (ON) has 
recently led to the differentiation of MOG immunoglobulin 
G associated optic neuritis (MOG-ON) from the more com-
mon idiopathic or multiple sclerosis (MS) associated optic 
neuritis (MS-ON) [1, 2]. Clinically, MOG-ON is character-
ized by a higher likelihood of bilateral disease, recurrent 
episodes, and involvement of the anterior optic nerve with 
associated disc edema compared to MS-ON [2–4]. Vision 
loss is often severe but with good recovery of vision [2]; 
recurrent episodes of MOG-ON can lead to poor visual out-
comes in approximately a quarter of patients [2, 3].
Optical coherence tomography (OCT) is widely deployed 
in ophthalmology to quantify and monitor optic neuropa-
thies, most frequently via the peripapillary nerve fiber layer 
(pRNFL). It has recently been shown that adding the macu-
lar ganglion cell layer (mGCL) thickness may have a better 
sensitivity than pRNFL alone in detecting optic neuropa-
thies, and that the distribution of mGCL loss may provide 
additional localizing value of optic neuropathies [5, 6].
OCT characteristics of MOG-ON have to date been less 
well studied with sometimes conflicting results. Havla et al. 
found that ON eyes of MOG-antibody positive patients 
show reduced pRNFL thickness of the temporo-inferior und 
temporo-superior quadrants and reduced macular RNFL 
thickness in comparison to MS-ON [7]. In contrast, in com-
parison to MS-ON, Martinez et al. found no significant dif-
ferences in the thickness of different retinal layers in six eyes 
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with MOG-ON [8]. More recently, Sotirchos et al. found a 
decrease in thickness of the macular ganglion cell and inner 
plexiform layer (IPL) of MOG-ON as compared to MS-ON 
[9]. A small case series of three patients with MOG-ON 
reported preferential thinning of pRNFL of some quadrants 
[10], which is in contrast to the thinning of the temporal 
pRNFL quadrant typically seen in MS optic neuritis [11]. 
Altogether, these studies have to be interpreted with cau-
tion due to limited sample sizes, potentially explaining the 
conflicting findings.
This study aims to characterize the morphological features 
of MOG-ON in comparison to MS-ON and correlate these 
with visual function. Given the reported anterior involve-
ment of the optic nerve in MOG-ON, the profound acute 
vision loss as compared to MS-ON and personal anecdotal 
evidence of a case that was initially misdiagnosed, we won-
dered whether MOG-ON shares morphological and func-
tional features with anterior ischemic optic neuropathy. The 
latter is typically associated with an irreversible nerve fiber 
bundle loss. We hypothesized that MOG-ON may result in 
more retinal nerve fiber bundle defects than MS-ON resulting 
in atrophy predominantly localized in the distribution of the 
nerve fiber bundles. To investigate this hypothesis, we sought 
to determine if changes in thickness of the retinal layers were 
uniform across the macula or if the thickness varied particu-
larly with respect to the horizontal raphe and the superior and 
inferior arcuate fibers of the macula.
Methods
Study design and patients
For this single-center retrospective study, we screened all 
patients examined at the Department of Ophthalmology, 
Inselspital, Bern, Switzerland between January 2006 and 
June 2018 for a diagnosis of MOG-ON or MS-ON by using 
the German translation of the keywords “neuritis” and 
“MOG” or “multiple sclerosis”. For the MOG group, eight 
patients were found with a total of 13 ON eyes; for the MS 
group, 95 patients with a total of 134 ON eyes. Inclusion cri-
teria were confirmed diagnosis of MOG antibody associated 
disease (by antibody testing and neurologist) or MS (by neu-
rologist) associated ON (diagnosed by an ophthalmologist) 
and availability of high resolution OCT images. There was 
no minimum follow-up for inclusion. Eyes with other rel-
evant ocular diagnoses were excluded. In addition, a healthy 
control (CTRL) group was established by including avail-
able examination results of known healthy persons. Evalua-
tion parameters for this study were visual acuity, visual field 
and retinal layer thicknesses (peripapillary and macular). 
This study was approved by the local cantonal ethics com-
mittee Bern under the project ID 2018-01151.
MOG‑immunoglobulin G testing
MOG status was tested using a cell-based assay (from 2015 
until 04/2017: FACS assay, University Hospital Basel, Prof. 
Derfuss, Basel, Switzerland [12, 13] abbreviated as FACS; 
since 05/2017: commercial IIFT, Euroimmun AG, Lübeck, 
Germany, measured in-house, abbreviated as EUROIM-
MUN). The FACS assay results were classified as positive, 
borderline or negative. The in-house assay EUROIMMUN 
results were expressed as titers (< 1:10 negative, 1:10 bor-
derline, > 1:10 positive).
Clinical ophthalmic examinations
Affected eye laterality, number of ON attacks, monocular 
best corrected visual acuity (BCVA, transformed to Log-
MAR) and color vision using Ishihara-plates were collected 
for each patient for each visit. Mean visual field defect (MD) 
and the square root of Loss Variance (sLV) were determined 
from an Octopus 900 system with the EyeSuite software 
(Haag-Streit Diagnostics, Koeniz, Switzerland). Visual acu-
ity corresponding to counting fingers and hand movements 
were rated as 1.854 and 2.301 in LogMAR values according 
to previously published quantitative data [14].
Imaging/OCT
The OCT images (30° × 30°) of macular volume scans 
(20° × 20°) consisting of 49 line B-scans were taken with a 
Spectralis HRA OCT (Heidelberg Engineering, Heidelberg, 
Germany). They were exported from the OCT system software 
HEYEX which comes with the Spectralis HRA OCT using the 
included XML export tool. The pRNFL-thickness of each sec-
tor and global pRNFL was exported directly from the HEYEX 
which measured pRNFL thickness along a ring of 3.6 mm 
diameter centered on the disc. Segmentation of the macular vol-
ume scans was performed using OCTSeg (ARTORG Center, 
Inselspital, Bern, Switzerland) which is a custom established 
OCT Segmentation tool previously described [15–17]. The 
automated segmentation separated the retinal layers by deter-
mining the border between the internal limiting membrane 
(ILM), the ganglion cell layer (GCL), the inner nuclear layer 
(INL), outer nuclear layer (ONL), junction of the inner and 
the outer nuclear segments, the outer segment of photorecep-
tors/pigment epithelium complex and the Bruch membrane. 
Processed segmentation was checked by an experienced reader 
(RV), blinded to the group and manually corrected if required. 
Based on these borders, we determined the thickness of the 
combined GCL and IPL (GCIPL), the combined macular INL 
and outer plexiform layer (INOPL) and the complete retina 
thickness (CRT). An Early Treatment Diabetic Retinopathy 
Study (ETDRS) grid was centered over the fovea and the aver-
age thickness measurement values for each sector and cell layer 
Journal of Neurology 
1 3
were computed by the software and exported. Grayscale images 
of the thickness of retinal layers were generated by OCTSeg. 
The greyscale images corresponding to the GCIPL of all 
included study subjects were stacked with Fiji software [18], 
images of left eyes were flipped horizontally, and all images 
were manually aligned. Using the included tool ROIManager, 
a circular grid with five circles and 16 sectors for each circle 
was inserted over the stack, resulting in 80 regions of interest 
(Fig. 2) for which measurements of all images were performed 
and exported. All thickness values are shown in micrometers.
Statistical analysis
Visual acuity as LogMAR, visual field values as MD and sLV 
and retinal layer thickness were evaluated. Mean values were 
compared using independent two-sample, one-sided Student’s t 
test for morphological parameters and an independent two-sam-
ple, two sided Student’s t test for the other parameters (Excel 
2016, Microsoft Corporation). Correlation of parameters were 
computed with the Pearson test (MATLAB R2019, The Math-
Works Inc.). Values are reported as mean ± standard deviation 
(SD) of the mean. To determine thickness steps, the GCIPL 
thickness values of horizontally mirrored sectors are divided by 
each other, in detail the higher value by the lower value of the 
two, to calculate the ratio. Three pooled sectors, representing 
nerve fiber bundles, were defined for a priori comparison with 
their mirrored counterpart; 17&18, 33&34 and 18&34. Figures 
were created using the export tool from HEYEX and Adobe 
Illustrator CC 2017 (Adobe Inc., San Jose, USA).
Results
Demographic and clinical characteristics of patients 
and CTRL
We found 11 eyes of six MOG antibody seropositive patients 
with confirmed optic neuritis and OCT images of good 
Table 1  Demographics of MOG patients, MS patients and healthy controls (CTRL) with the corresponding measures of visual function
BCVA best corrected visual acuity, MD mean defect, sLV square root of loss variance, SD standard deviation
a MOG n = 9/MS n = 16
Bold values indicate statistical significance with a p-value less than 0.05
Group, number of eyes/
variables
MOG n = 11 MS n = 22 CTRL n = 33 p value 
MOG/
MS
p value MOG/CTRL p value MS/CTRL
Age in years, mean 
(SD), [min:max]
26.25 (11.80) 
[10.28:46.56]
29.59 (9.13) 
[17.27:53.07]
26.30 (10.98) 
[9.13:46.59]
0.392 0.990 0.259
Female, n (%) 5 (45.5) 10 (45.5) 15 (45.5) 1.000 1.000 1.000
Age at first onset of ON 
in years, mean (SD), 
[min:max]
22.99 (11.79) 
[9.94:45.82]
26.54 (7.63) 
[15.82:46.06]
– 0.321 – –
Number of ON epi-
sodes, mean (SD), 
[min:max]
1.18 (1) [1:2] 1.05 (1) [1:2] – 0.211 – –
Time between onset of 
ON and last examina-
tion in months, mean 
(SD), [min:max]
40 (33) [4:105] 40 (37) [1:130] – 1.000 – –
Last BCVA LogMAR, 
mean (SD)
0.24 (0.40) 0.28 (0.61) − 0.07 (0.08) 0.831 < 0.0002 0.0023
BCVA at nadir, Log-
MAR (SD)
1.09 (0.66) 0.51 (0.75) – 0.043 – –
BCVA recovery at last 
examination, Log-
MAR (SD)
0.85 (0.74) 0.22 (0.46) – 0.007 – –
Last visual field, MD 
(SD)a
7.63 (5.17) 4.94 (4.50) – 0.205 – –
Last visual field, sLV 
(SD)a
4.53 (2.38) 4.23 (2.55) – 0.782 – –
Visual field recovery, 
MD (SD)a
1.91 (1.60) 1.92 (3.37) – 0.995 – –
Visual field recovery, 
sLV (SD)a
0.77 (0.93) 0.88 (1.56) – 0.863 – –
 Journal of Neurology
1 3
quality which could be used for the MOG group. The MS 
group consisted of 22 age and sex matched eyes of 17 MS 
patients, the CTRL group of 33 age and sex matched eyes 
of 20 healthy persons. Included patients were seen between 
2011 and 2018. The two patient groups were comparable in 
age at time of onset of the ON, number of ON episodes and 
time between onset of ON and the last examination avail-
able. Visual field values were only available for nine eyes 
of the MOG group and 16 eyes of the MS group. Analysis 
including visual field values were only performed for eyes 
where the values were available.
Demographic and clinical characteristics of MOG-ON 
eyes, MS-ON eyes and CTRL are shown in Table 1.
Function: MOG‑ON eyes vs. matched MS‑ON eyes vs. 
CTRL eyes
In comparison to the MS group, the BCVA at nadir of our 
MOG group after ON was significantly worse, whereas 
the recovery of the visual acuity, defined as the difference 
between BCVA at nadir and BCVA at the last examina-
tion, was significantly better. This resulted in comparable 
mean BCVA on the final examination. The time between the 
examination at nadir and the last examination did not differ 
significantly between groups (Table 1).
Compared to the CTRL group, both patient groups had a 
significantly worse BCVA on the last examination. Visual 
field MD on the last examination was slightly higher in the 
MOG group than the MS group, but the difference was not 
significant (Table 1).
Morphology: MOG‑ON eyes vs. matched MS‑ON eyes 
vs. CTRL eyes
In our study, the MOG group shows a significantly lower 
global pRNFL thickness compared to the MS group and the 
CTRL group. A significantly lower global pRNFL can also 
be seen for the MS group compared to the CTRL group. 
When pRNFL is split up into sectors, the MOG group shows 
significantly thinner pRNFL in the nasal, naso-inferior 
and temporo-superior sectors compared to the MS group 
(Table 2, Fig. 1).
GCIPL thickness of the inner ring of the ETDRS grid is 
significantly lower in both patient groups compared to the 
CTRL group without a significant difference between the 
two patient groups. A slightly higher INOPL thickness can 
be found in the MOG group compared to the CTRL group 
in the superior and a slightly lower INOPL thickness in the 
inferior inner sector (Table 2, Fig. 1). The a priori com-
parisons of the three pooled sectors and their horizontally 
mirrored counterparts do not show any significant thick-
ness step differences over the horizontal raphe when the 
two patient groups are compared to each other. However, 
we found some significant differences between each patient 
group and CTRL group in other pooled sectors ratios to its 
mirrored counterparts (Fig. 2).
Morphology‑function: MOG‑ab associated ON eyes 
vs. matched MS associated ON eyes
Eyes of the MOG group show an inverse correlation of 
the ratio of the ETDRS inner ring GCIPL thickness to 
Table 2  Morphology measurements for peripapillary retinal nerve fiber layer (pRNFL), ganglion cell and inner plexiform layer (GCIPL) and 
inner nuclear and outer plexiform layer (INOPL) of different regions of MOG patients, MS patients and healthy controls (CTRL)
N nasal, T temporal, I inferior, S superior
Bold values indicate statistical significance with a p-value less than 0.05
Group, number of eyes/variables MOG n = 11 MS n = 22 CTRL n = 33 p value 
MOG/
MS
p value MOG/CTRL p value MS/CTRL
pRNFL global, mean (SD) 59.45 (19.58) 75.27 (21.54) 102.85 (9.08) 0.028 < 0.0001 < 0.0001
pRNFL NS, mean (SD) 76.36 (28.41) 89.68 (31.15) 113.73 (18.04) 0.128 < 0.0001 0.0004
pRNFL N, mean (SD) 43.64 (17.71) 60.27 (21.84) 78.39 (10.95) 0.021 < 0.0001 0.0001
pRNFL NI, mean (SD) 65.55 (20.93) 85.59 (23.81) 117.88 (23.27) 0.014 < 0.0001 < 0.0001
pRNFL TI, mean (SD) 84.64 (30.28) 106.00 (40.32) 147.21 (20.98) 0.071 < 0.0001 < 0.0001
pRNFL T, mean (SD) 37.45 (13.59) 45.68 (15.40) 69.64 (8.46) 0.078 < 0.0001 < 0.0001
pRNFL TS, mean (SD) 86.91 (31.25) 110.59 (25.65) 147.82 (14.95) 0.016 < 0.0001 < 0.0001
GCIPL, mean (SD) 74.64 (10.95) 75.95 (10.27) 99.14 (4.83) 0.373 < 0.0001 < 0.0001
INOPL, mean (SD) 70.25 (3.10) 69.25 (0.92) 69.42 (0.75) 0.092 0.085 0.474
INOPL N1, mean (SD) 71.28 (9.28) 68.12 (3.75) 68.23 (3.16) 0.094 0.060 0.452
INOPL S1, mean (SD) 71.96 (3.30) 70.55 (0.37) 70.70 (0.27) 0.032 0.020 0.047
INOPL T1, mean (SD) 67.85 (1.91) 67.89 (1.86) 68.24 (1.84) 0.479 0.278 0.249
INOPL I1, mean (SD) 69.91 (0.81) 70.44 (1.15) 70.48 (0.29) 0.099 0.001 0.417
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CRT with visual function parameters such that thinning 
correlates with decreased function; the strongest and most 
significant can be found for the correlation of GCIPLr 
to visual field MD. When single sectors of the ETDRS 
grid inner ring (Fig.  1f, g) are compared to function 
parameters, the inferior sector shows the strongest nega-
tive correlation with R2 values > 0.4 for all three param-
eters (BCVA, visual field MD and sLV). In the MS group 
there is no significant correlation between GCIPLr and 
functional parameters (Table 3).
Fig. 1  Clinical OCT output of a MOG-ON patient and differences 
in nerve fiber layer thickness. a Shows the OCT infrared scan of the 
optic disc and peripapillary region, b shows a vertical profile of the 
retina and the pRNFL corresponding to the location of the (green) 
ring in the OCT infrared scan. The two drawn lines represent the bor-
ders of the pRNFL. c Shows a sample of the mean thicknesses of the 
pRNFL of the different sectors whereas d shows the thickness pro-
file of the pRNFL corresponding to the (green) ring and underlaid the 
normative values (green/top = normal, yellow/middle = borderline, 
red/bottom = pathologic). e Highlights the segments with significant 
differences in pRNFL thickness between MOG group and MS group, 
f shows an OCT infrared scan of the macula of a MOG-ON patient 
with an ETDRS grid overlay. g Highlights the significant differences 
in INOPL thickness in superior and inferior segments of the inner 
ring of the ETDRS grid when MOG and CTRL group is compared
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Discussion
In this retrospective case series, we found a more severe 
vision loss at nadir in MOG-ON compared to MS-ON. 
The visual recovery, however, was significantly better in 
the MOG patients such that the final visual outcome was 
comparable between the two disease groups. Regarding 
morphological changes, we found a significant reduction 
of the peripapillary retinal nerve fiber layer and macular 
ganglion cell layer on the last examination in both disease 
groups as compared to healthy controls. The morphology 
of MOG and MS associated optic neuropathy seems rela-
tively similar with some differences: MOG-ON shows a 
significantly thinner pRNFL in the overall pRNFL thick-
ness which is likely driven by significantly thinner pRNFL 
in the superior and inferior parts of the pRNFL, while the 
temporal thinning seems similar in MS-ON and MOG-
ON. These findings seem to parallel the functional findings 
with worse visual fields in MOG (although not statistically 
significant) and equal or even slightly better visual acu-
ity (also not statistically significant) in MOG-ON as com-
pared to MS on the last examination. The GCIPL thickness 
in contrast seems equal in both disease groups, which cor-
responds to the equal visual acuity on the last examination. 
Taken together this data suggests a more profound optic 
neuropathy after a single episode of MOG-ON compared 
to MS-ON and a tendency to affect the visual field more 
than the visual acuity as a long-term outcome. As a poten-
tial OCT correlate, MOG-ON seems to affect the superior 
and inferior portions of the optic nerve more than MS-ON, 
while involvement of central (i.e., macular) ganglion cells 
and visual acuity is similar in the two disease groups.
We could not confirm our initial hypothesis of an asym-
metric nerve fiber bundle loss in one or the other disease 
group, i.e., we found that the vertical asymmetry, which is 
a hallmark of ischemic optic neuropathy with its associated 
Fig. 2  Regions of interest over the Macula for GCIPL comparison 
and thickness steps over the horizontal raphe. The left image shows 
an overlay of the OCT infrared scan of the macula and the grid with 
regions of interest used for this study. The graphics in the right part 
show the same regions of interest, highlighted are the regions which 
show significantly different ratios between its horizontally mirrored 
counterparts when MOG group and MS group respectively are com-
pared to CTRL group. For simplification only the upper half is shown
Table 3  Correlation analysis of OCT measures and visual function parameters: table depicts correlation coefficient/R2/p value and 95% confi-
dence interval; ganglion cell and inner plexiform layer ratio to complete retina thickness (GCIPLr) of the inner ring of the ETDRS grid
Bold values indicate statistical significance with a p-value less than 0.05
Var1/Var2 corr MOG MS
GCIPLr BCVA − 0.55/0.30/0.08 [− 0.86; 0.08] − 0.23/0.05/0.30 [− 0.59; 0.21]
GCIPLr MD − 0.76/0.57/0.02 [− 0.95; − 0.20] − 0.12/0.01/0.66 [− 0.58; 0.40]
GCIPLr sLV − 0.66/0.43/0.05 [− 0.92; 0.01] − 0.23/0.05/0.40 [− 0.65; 0.30]
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nerve fiber bundle loss, is not present or not different in 
MS-ON and MOG-ON. Although our data indicate a more 
profound involvement of superior and inferior nerve fiber 
bundles in MOG-ON, there was no significant vertical 
asymmetry in this involvement. This argues against a vas-
cular component of the optic neuropathy as seen in anterior 
ischemic optic neuropathy where differences in superior and 
inferior GCIPL layer thickness have been described [19, 20].
Regarding OCT characteristics, our study confirms previ-
ous findings of a significantly decreased thickness in global 
pRNFL of MOG-ON eyes in comparison to healthy eyes as 
well as MS-ON eyes [7]. The more pronounced thinning of 
the pRNFL may be a consequence of more profound inflam-
mation in the acute disease phase and correlate with the 
worse vision in the acute phase of MOG-ON. The GCIPL 
ETDRS inner ring thickness did not differ significantly 
between the MOG and MS group despite the significant 
difference in pRNFL thickness between the groups. This 
might be explained by the distribution of pRNFL thinning 
in MOG-ON: the temporal-superior, nasal and nasal-inferior 
segments are more affected in MOG-ON than MS-ON, but 
both entities show similar thinning in the temporal pRNFL 
segment, which is comprised of nerve fibers heading to the 
macula, resulting in similar macular GCIPL thickness. These 
results may correspond to published data by Havla et al. who 
showed more severe thinning in the temporal inferior and 
temporal superior sectors when comparing MOG-ON to 
MS-ON but no significant difference in the temporal sec-
tor [7]. However, Sotirchos et al. found differences in the 
temporal pRNFL comparing MOG-ON to MS-ON and in 
thinning of GCIPL between these two groups, highlighting 
the conflicting findings in the literature due to limited sam-
ple sizes in all studies [9]. As temporal pRNFL thickness 
of MS-ON eyes does not differ significantly from temporal 
pRNFL thickness in neuromyelitis optica spectrum disor-
ders (NMOSD) [11], the latter of which are known to result 
in severe atrophy [21] the similar outcome between tem-
poral pRNFL thickness in MOG-ON and MS-ON may be 
due to relatively more severe temporal thinning in MS-ON 
rather than less severe temporal thinning in MOG-ON. This 
similarity in temporal pRNFL thickness corresponds to the 
similar BCVA at last examination between the two patient 
groups.
The correlation of morphology and function was clearer 
in the MOG group. Each visual function parameter (BCVA 
at last examination, MD of the visual field and sLV of the 
visual field) showed a negative correlation for the ratio of 
the GCIPL to CRT, which supports the correlation between 
OCT findings and visual field loss as well as BCVA 
described in smaller cohorts [22]. This correlation may have 
future implications for prognosis in patients with MOG-ON 
whereas the morphological findings in MS-ON appear less 
predictive of visual function. These findings are consistent 
with the lack of correlation between GCL thickness and high 
contrast visual acuity despite correlation of GCL thickness 
with low contrast visual acuity previously described in 
MS-ON [23, 24].
We found a worse visual acuity at nadir in the MOG-ON 
group in our cohort with a worst BCVA around one. This 
result supports the findings of Jarius et al. who found over 
two thirds of MOG-ON patients presenting at least once 
with BCVA worse than one [2]. The underlying reason for 
the better recovery of vision is still unclear; a potential cor-
relate to decreasing MOG-antibody serum concentrations 
with reduced inflammatory activity in remission following 
the acute phase of the disease is thus far speculative [4, 12, 
25]. Our study did not show a significant difference in the 
number of bilateral cases of optic neuritis in the MOG group 
compared to the MS group; similarly, we did not show a sig-
nificant difference in the number of recurrent episodes. These 
findings are likely due to a small sample size of 11 eyes in the 
MOG group and not a refutation of these previously reported 
characteristics [2]. The results are summarized in Table 4 and 
shown in Fig. 1 graphic “e” and “g” and Fig. 2.
Our study has several limitations. Most importantly, our 
sample size is small and larger studies are needed for corrob-
oration of our findings. An additional important limitation 
is testing bias in the diagnosis of MOG-ON; as this entity 
is only recently described, testing for MOG-IgG antibodies 
may have predominantly been performed only in severe or 
bilateral cases of optic neuritis. This bias in testing would 
skew our analysis towards more severe cases in the MOG-
ON group, with correspondingly more severe OCT findings. 
In addition, although follow-up time is similar between 
groups, it is still relatively short in terms of a chronic disease 
such that recurrent disease is likely underrepresented in our 
study. Furthermore, vision before ON was not documented 
and some eyes may have an undiagnosed pre-existing ON. 
We were not able to include cases of NMOSD eyes in our 
study, which would be an additional cohort of interest.
Table 4  Summary of the 
findings
Differences in MOG-ON compared to MS-ON Similarities between MOG-ON and MS-ON
Significantly thinner global pRNFL in MOG-ON Similar thinning of the temporal pRNFL
Inverse correlation of macular ganglion cell layer 
thickness with visual function in MOG-ON
Similar thinning of the macular ganglion cell layer
Worse visual acuity at nadir in MOG-ON Similar visual acuity at last examination
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Conclusion
MOG-ON should be considered in all patients with ON 
with an atypical or more severe clinical course. MOG-
ON was associated with more prominent acute vision loss 
than MS-ON but resulted in similar final visual acuity. In 
comparison to MS-ON, we found a significantly decreased 
thickness in global pRNFL in MOG-ON and no significant 
difference in the GCIPL thickness. The GCIPL thickness 
showed a significant inverse correlation with MD in visual 
fields in MOG-ON, but not MS-ON, which may have future 
prognostic implications in MOG-ON.
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